targeted cancer therapy

February 16, 2023

Targeted therapy for neuroendocrine tumors

Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.

By Kelsey Pinckard
Pregnant woman holding pill pack
August 2, 2022

Targeted cancer drug during pregnancy

The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

By Leigh MacMillan
April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

By Leigh MacMillan
February 24, 2022

Melanoma treatment response

Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

By Sarah E. Glass
June 22, 2021

Treating metastatic prostate cancer

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

By Leigh MacMillan
From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.
April 11, 2019

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

By Tom Wilemon
June 14, 2017

PET imaging to predict tumor response

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.
By Leigh MacMillan
May 3, 2016

Drug combos for glioblastoma

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
By Leigh MacMillan
March 10, 2016

IOM study calls for better evidence for biomarker tests

Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine.
By VUMC News and Communications
February 10, 2016

Overcoming lung cancer drug resistance

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.
By Marilyn Holt
August 28, 2014

Limiting breast cancer metastasis

Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.
By Brandon Turner
August 5, 2014

Drug discovery clues in network map

Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies.
By Bill Snyder
July 31, 2014

New target for breast cancer therapy

The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics.
By Leigh MacMillan
1 2